RGD peptides may only temporarily inhibit cell adhesion to fibronectin  by Ylänne, Jari
Volume 267, number 1, 43-45 FEBS 08546 July 1990 
RGD peptides may only temporarily inhibit cell adhesion to fibronectin 
Jari Ylhne 
Department of Anatomy. Unwersity of Helsinki, Siltavuorenpenger 20 A, 00170 Helsinki, Finland 
Received 14 Apt-11 1990 
When human fibroblasts were cultured on fibronectin for 4 h in the presence of 0 5 mg/ml of the GRGDSP pepttde derived from the fibronectin 
cell-bmdmg site. they adhered and spread normally and orgamzed talin and integrm t(s and 8, subunits mto focal adhesions. When the adherent 
cells were quantitated as a function of time, submaximal peptide concentrattons were found to delay cell adhesion on Iibronectm, but they had 
no effect on the maximum. When the cells were plated on vitronectm, however, even relatively low pepttde concentrations lowered the maximal 
amount of cells adhering and abolished ceil spreading. The results suggest a dtfferent mechamsm for cell adhesion on fibronectin and vitronectm 
Cell adhesion. Fibronectin. Vttronectm; Integrin; Fibronectm pepttde 
1. INTRODUCTION 
Synthetic peptides, containing the sequence RGD 
(Arg-Gly-Asp) or some of its variants, have been shown 
to inhibit adhesion of various cells to several ex- 
tracellular matrix proteins including fibronectin, 
vitronectin, von Willebrand factor, fibrinogen, throm- 
bospondin and osteopontin [l]. The sequence was first 
found in fibronectin [2] and mapped as the main in- 
teraction site for the cell surface fibronectin-binding 
protein, the LYS/,~I integrin [3]. This protein also in- 
teracts with cytoskeletal proteins at the focal adhesions 
[4], thus regulating the organization of cytoskeleton 
when cells adhere and spread on fibronectin. RGD pep- 
tides have been used to inhibit the function of the QUS/~~ 
complex and other integrins in several experimental 
models, including experimental metastasis [5] and cell 
migration [6]. 
serum albumin solution (Sigma, St. Louis, MO). To quantitate the 
adhered cells, the cultures were first labelled with IO &i/ml of [35S]- 
methtonine (Amersham Internattonal, Amersham, UK) for 12 h and 
then seeded on the multiwell dishes. For some experiments monensin 
(10 FM; Eli Lilly, Indianapolis, IN) was simultaneously added. After 
indicated time periods the wells were washed, and the adherent cells 
were solubilized in 0.5 M NaOH, 1% SDS, and counted in a liquid 
scintillation counter. The results are shown as mean ? SE values from 
4 separate experiments. 
3 ,, RESULTS 
2. MATERIALS AND METHODS 
Human embryonic ftbroblasts (code F84-67) were obtained from a 
local source, GRGDSP and GRGES peptides were from Multiple 
Peptide Systems Inc. (San Diego, CA), and the rat monoclonal an- 
tibody BlE5 against the cy integrin subunit from Dr C. Damsky (San 
Francisco, CA) [7]. The mouse monoclonal antibody against the /3i 
integrin subunit (102DF5) has been characterized earlier [8]. For in- 
direct immunofluorescence microscopy fluorochrome-coupled sheep 
anti-mouse or goat anti-rat IgG antisera (Cappel, Organon Teknika, 
West Chester, PA) were used. Adhesion experiments were done m 
serum-free RPM1 1640 medium on glass coverslips or 96-well 
multiwell dishes (Nunc, Kamstrup, Denmark) treated for 1 h (at 
room temperature) with 20 pg/ml of human ftbronectin or vitronec- 
tm (purified as in [9,10]) followed by treatment with 1% bovine 
When human fibroblasts were plated on fibronectin- 
treated surfaces in the presence of 0.5 mg/ml of the 
synthetic GRGDSP peptide, their initial adhesion was 
diminished with about 50%. However, within 4 h the 
same amount of cells had been attached as in the con- 
trol (Fig. lA), the cells had spread, and the ,8i and a5 
integrin subunits (Fig. 2), as well as talin (not shown) 
were detected at focal adhesions. At this time the 
peptide-exposed cells still showed diminished organiza- 
tion of fibronectin fibers (not shown, see [l 11) and the 
organization of the Pi and cyg integrins in structures 
coaligning with these fibers was also less prominent 
than in the control cells (Fig. 2). 1.5 mg/ml of the pep- 
tide completely inhibited cell adhesion on fibronectin 
(Fig. 1A). 
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On vitronectin-coated surfaces 0.5 mg/ml of the 
GRGDSP peptide almost completely inhibited cell 
adhesion. 0.005 mg/ml of the peptide, which caused 
50% inhibition of cell adhesion within 1 h, also 
diminished the maximal adhesion reached within 4 h, 
as did even 0.001 mg/ml of the peptide (Fig. 1B). 
Even the low concentrations blocked cell spreading on 
vitronectin (not shown). To study whether the different 
effects of the peptide to cell spreading on vitronectin 
and on fibronectin was dependent on cellular secretion 
of proteins, adhesion experiments on fibronectin were 
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Fig. 1. Adhesion of human fibroblasts on ftbronectin (A and C) or 
on vitronectin (B) in the presence of vartous concentrations of 
GRGDSP peptide. In each panel 100% represents the maximal 
adhesion reached in the particular experiment. (A) (~8) Control 
without the pepttde; (-) control with 1.5 m&ml of the Inactive 
GRGES peptide; (+) 0.5 mg/ml GRGDSP; (x) 1.5 mg/ml 
GRGDSP. (B) (a) Control without the peptide; (+) 0.001 mg/ml 
GRGDSP; (x) 0.005 mg/ml GRGDSP; (*) 0.5 mg/ml GRGDSP: 
(-) background adhesion on BSA-coated surfaces. (C) Adhesion on 
fibronectin m the presence (dashed line) or absence of monensm 
(solid line) and wtthout (:?) or with (w) 0.25 mg/ml GRGDSP 
peptrde. 
also made in the presence of IOpM monensin, which 
blocks cellular secretion. Although monensin reduced 
the amount of adhered radioactivity, it only slightly 
prolonged the inhibition effect of the peptide, and 
similar maximal adhesion was reached as in the absence 
of the peptide and in the presence of monensin 
(Fig. 1C). 
4. DISCUSSION 
GRGDSP [12] or GRGDS [13] peptides have been 
shown to be the most active among RGD-containing 
peptides in the inhibition of cell adhesion on fibronec- 
tin. Some differences in the inhibitory ability have been 
noted between different cells [13], and the peptides are 
commonly more potent inhibitors of cell adhesion on 
vitronectin than on fibronectin [12,13]. The inhibitory 
activity of the peptides has usually been measured in 
short term (30 min- 1 h) adhesion assays [ 12,131. Here 
I have shown that, at least in human fibroblasts, pep- 
tide concentrations that may cause 50% inhibition of 
cell adhesion in short term assays only delayed the 
adhesion on fibronectin, but caused a more permanent 
inhibition of adhesion and spreading on vitronectin. 
This difference cannot be explained by that the cells 
would use the secreted fibronectin for adhesion, since 
(i) the cells most probably secrete similar amounts of 
fibronectin either when cultured on fibronectin or on 
vitronectin, but on vitronectin the inhibitory effect of 
the RGD peptide does not cease within 4 h, and (ii) 
blocking the secretion had no prominent effect on the 
inhibition. The possibility of different degradation 
rates of the peptide on the two culture substrata is also 
quite unprobable. Monensin, however, slightly decreas- 
ed the amount of radioactivity adhered to the 
substratum, but this might be explained by its 
nonspecific effects. 
The observed difference in the long term inhibition 
effect of the RGD peptide suggests that fibroblasts 
might use different mechanisms of adhesion on 
fibronectin than on vitronectin. Apparently, several co- 
operative cell-fibronectin interaction sites [ 14,151 are 
used and the adhesion is less sensitive to blocking of the 
RGD site, while such co-operative sites have not been 
described for vitronectin. 
The present finding may be important, when various 
applications of the RGD peptides are developed. It is 
possible that the phenomenon reported here is cell-type 
specific. Anyway, it seems that when fibroblasts are 
allowed to attach on fibronectin under stationary con- 
ditions, huge amounts of GRGDSP or related peptides 
are needed to inhibit the adhesion process. Such con- 
centrations may be highly toxic in vivo. On the other 
hand, under dynamic conditions, in which the rate of 
initial attachment might be the delimiting step in cell 
adhesion to fibronectin, as well as in the cases where 
other matrix proteins than fibronectin are the promi- 
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Fig. 2. Localization of thepi (a, b) and (~5 (c, d) integrin subunits by indirect immunofluorescence microscopy. Human fibroblasts were cultured 
for 4 h on fibronectin in the absence (a, c) or presence of 0.5 mg/ml GRGDSP peptide (b, d). Arrows pomt at the focal adhestons which can 
be seen in each case, and arrowheads (a, c) at the fibrillar structures, which are less prominent in the presence of the peptide (b, d). 
nent adhesive components, the peptides may be used in 
much lower concentrations. 
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